Acasti Pharma
ACST

$2.76

2.47%

Market Cap: 25.9M

About: Acasti Pharma Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. Its novel drug delivery technologies have the potential to improve the performance of marketed drugs by achieving faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery all of which could help to increase treatment compliance and improve patient outcomes.

Employees: 4

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,702 funds

–

Analysts bullish %

–

News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

163% more capital invested

Capital invested by funds: $1.65M [Q4 2023] → $4.34M (+$2.69M) [Q1 2024]

100% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 2

25% more funds holding

Funds holding: 8 [Q4 2023] → 10 (+2) [Q1 2024]

7.38% more ownership

Funds ownership: 6.08% [Q4 2023] → 13.46% (+7.38%) [Q1 2024]

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price forecasts over the past 6 months

Low target

$6

117%

upside

Avg. target

$6

117%

upside

High target

$6

117%

upside

1 analyst rating

1 positive

100%

0 neutral

0%

0 negative

0%

Craig-Hallum

Chase Knickerbocker

117%upside

$6

Buy

Initiated

7 Feb 2024

See Analyst Rankings

Financial journalist opinion

Zacks Investment Research

Is Acasti Pharma (ACST) Outperforming Other Medical Stocks This Year?

Here is how Acasti Pharma (ACST) and Cigna (CI) have performed compared to their sector so far this year.

Is Acasti Pharma (ACST) Outperforming Other Medical Stocks This Year?

Acasti Announces Achievement of 50% Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial

Company Anticipates Completion of Patient Enrollment in the STRIVE-ON Trial in Late 2024 to Early 2025, with Potential NDA Submission on Track for 1H Calendar 2025 Company Anticipates Completion of Patient Enrollment in the STRIVE-ON Trial in Late 2024 to Early 2025, with Potential NDA Submission on Track for 1H Calendar 2025

Acasti Announces Achievement of 50% Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial

Acasti Announces Year-End 2024 Financial Results, Provides Business Update

PRINCETON, N.J., June 21, 2024 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel injectable formulation of nimodipine that addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (aSAH), today announced financial results and business highlights for the year ended March 31, 2024.

Acasti Announces Year-End 2024 Financial Results, Provides Business Update

Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for June 2024

As the main stock indices like the S&P 500 and Nasdaq continue to climb, penny stocks are becoming attractive for those seeking significant returns. Despite their reputation for extreme price fluctuations and high risk, they offer the potential for impressive gains, especially in a bull market.

Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for June 2024

Acasti Pharma to Attend BIO International Convention 2024

PRINCETON, N.J., May 28, 2024 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel, injectable formulation of nimodipine that addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (aSAH), today announced that the Company will be participating in the BIO International Convention taking place at the San Diego Convention Center from June 3-6, 2024.

Acasti Pharma to Attend BIO International Convention 2024

The Next Novavax? 3 Biopharma Stocks to Buy Before They Boom

Novavax (NASDAQ: NVAX ) stock was among the laggards in the race for the vaccine against COVID-19. Unsurprisingly, NVAX stock plunged from highs of $320 in 2021 to recent lows of $3.5.

The Next Novavax? 3 Biopharma Stocks to Buy Before They Boom

Acasti Announces Third Fiscal Quarter 2024 Financial Results and Business Highlights

PRINCETON, N.J., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel formulation of nimodipine that addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (aSAH), today announced financial results and business highlights for the quarter ended December 31, 2023.

Acasti Announces Third Fiscal Quarter 2024 Financial Results and Business Highlights

Acasti Announces Poster Detailing its GTX-104 STRIVE-ON Trial

Accepted for Presentation at the 2024 International Stroke Conference Accepted for Presentation at the 2024 International Stroke Conference

Acasti Announces Poster Detailing its GTX-104 STRIVE-ON Trial

Acasti to Participate in Upcoming San Francisco Investor Conferences in January 2024

PRINCETON, N.J., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel intravenous formulation of nimodipine being developed to address the high unmet medical needs for a rare disease, aneurysmal Subarachnoid Hemorrhage (aSAH), today announced that Chief Executive Officer Prashant Kohli will participate in the following investor and industry networking events in San Francisco, California during the week of January 7-12, 2024.

Acasti to Participate in Upcoming San Francisco Investor Conferences in January 2024

See News Rankings